Biased Ligands. Better Drugs.

Press Releases

2/3/16 - Trevena to present at the 18th Annual BIO CEO & Investor Conference

Trevena, Inc. today announced that the company will be webcasting its corporate presentation at the 18th Annual BIO CEO & Investor Conference on Monday, February 8, 2016 at 4:30 p.m. EST in New York. Read More

1/19/16 - Trevena, Inc. Announces Initiation of Oliceridine Phase 3 Clinical Program
Trevena, Inc., today announced the launch of the oliceridine (TRV130) Phase 3 clinical program with the enrollment of patients in the open label Phase 3 ATHENA-1 study. Read More

12/16/15 - Trevena, Inc. added to NASDAQ Biotechnology Index (NBI)
Trevena, Inc., today announced that it has been selected for addition to the NASDAQ Biotechnology Index®. The selection will become effective upon market open on Monday, December 21, 2015. Read More

12/3/15 - Trevena Announces FDA Grant of Fast Track Designation to Oliceridine (TRV130)
Trevena, Inc. (NASDAQ: TRVN), today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to oliceridine (TRV130) for the management of moderate-to-severe acute pain. Read More

12/3/15 - Trevena Granted Key Composition of Matter and Use Patent for TRV027 in Europe
Trevena, Inc. (NASDAQ: TRVN), today announced that the European Patent Office has granted European Patent EP2376101B1, “Beta-Arrestin Effectors and Compositions and Methods of Use Thereof,” which covers the composition of matter for TRV027 and uses thereof. Read More

12/2/15 - Trevena to present at the Oppenheimer 26th Annual Healthcare Conference
Trevena, Inc. (NASDAQ: TRVN), today announced that the company will be webcasting its corporate presentation at the Oppenheimer 26th Annual Healthcare Conference on Tuesday, December 8, 2015 at 1:00 p.m. EST in New York. Read More

11/12/15 - Trevena CEO to present at the Jefferies 2015 Global Healthcare Conference
Trevena, Inc. (NASDAQ: TRVN), today announced Maxine Gowen, Ph.D., its chief executive officer, will present a company overview at the Jefferies 2015 Global Healthcare Conference on Thursday November 19, 2015 at 3:20 p.m. GMT (10:20 a.m. EST) in London. Read More

11/10/15 - Trevena Reports Third Quarter 2015 Financial Results and Provides Corporate Update
Trevena, Inc. (NASDAQ: TRVN), today announced financial results for the quarter ended September 30, 2015 and provided an update regarding its ongoing clinical programs. Read More

10/28/15 - Trevena Hosts Investor and Analyst Day
Trevena, Inc.,today hosted an Analyst and Investor Day in New York City that focused on the Company’s clinical programs, including its most advanced assets, TRV130 and TRV027. Read More

10/21/15 - Trevena to Host Analyst and Investor Day on October 28, 2015
Trevena, Inc. (NASDAQ: TRVN), today announced that it will host an Analyst and Investor Day on Wednesday, October 28, 2015 in New York City. Read More

9/29/15 - Trevena Announces Publication of TRV130 Phase 2 Bunionectomy Data in the Journal PAIN®
Trevena, Inc. (NASDAQ: TRVN), today announced the publication of the full results from its Phase 2a/b trial of TRV130 in postoperative pain following bunionectomy surgery in the online edition of PAIN®, the Journal of the International Association for the Study of Pain. The results successfully demonstrated proof of concept for TRV130, and suggested potential differentiation from morphine. Read More

9/16/15 - Trevena, Inc. Announces Closing of Public Offering of Common Stock
Trevena, Inc. (NASDAQ: TRVN), today announced the closing of its previously announced underwritten public offering of 7,475,000 shares of its common stock, including 975,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $9.75 per share. Read More

9/11/15 - Trevena, Inc. Announces Pricing of Underwritten Offering of Common Stock
Trevena, Inc. (NASDAQ: TRVN), today announced the pricing of an underwritten offering of 6,500,000 shares of its common stock, offered at a price to the public of $9.75 per share. Read More

9/10/15 - Trevena, Inc. Announces Proposed Underwritten Offering of Common Stock
Trevena, Inc. (NASDAQ: TRVN), today announced its intention to offer and sell shares of its common stock in an underwritten offering pursuant to an existing shelf registration statement. All of the shares in the proposed offering are to be sold by Trevena, Inc. Read More

9/8/15 - Trevena Announces Presentations at PAINWeek® 2015
Trevena, Inc. (NASDAQ: TRVN), today announced that the Company will present four posters at PAINWeek®, the National Conference on Pain for Frontline Practitioners, being held at The Cosmopolitan Las Vegas, in Las Vegas, NV from September 8 – 12, 2015. Read More

8/31/15 - Trevena Announces Positive Results from Phase 2b Study of TRV130 in Acute Postoperative Pain
Trevena, Inc. (NASDAQ: TRVN), today announced positive data from its randomized, double-blind, placebo- and active-controlled Phase 2b trial of TRV130 in moderate to severe acute postoperative pain after abdominoplasty surgery. The study achieved its primary endpoint of statistically greater pain reduction than placebo over 24 hours. In addition, TRV130 was superior to morphine in pre-specified secondary measures, exhibiting significantly reduced nausea, vomiting, and hypoventilation events. Read More

News Archive

Copyright © Trevena, Inc.